Division of Cardiology

Salim Yusuf

MD (Bangalore), DPhil (Oxford), MRCP

Professor, Division of Cardiology

Professor, Department of Medicine

Joint Member, Dept. of Clinical Epidemiology & Biostatistics

Heart and Stroke Foundation - Chair in Cardiology

Director, Population Health Research Institute

Administrative Assistant: Judy Lindeman


Academic Interests

Dr. Yusuf's recent interests include societal, biologic and genetic determinants of population health in developing populations, and his studies involve over 66 countries in all the inhabited continents of the world.

Societal & biologic determinants of diseases and evaluation of therapies in humans, with special focus on cardiovascular diseases, obesity, and diabetes.

The specific topics currently under investigation:

  1. The role of various treatments and nutritional supplements in the prevention of atherosclerosis and major vascular events,
  2. The role of antithrombotic drugs
  3. The prevention of complications of diabetes
  4. Ethnic and international variations in heart disease with reference to biological markers, nutrition and psychosocial factors
  5. Impact of urbanization on health
  6. Childhood risk factors

The general methodology used has been the conduct of small and large randomized trials, large case-control and cohort studies, detailed physiological investigations, meta-analyses of previously published studies and analysis of national mortality data.

Selected Publications

  1. Yusuf S, Mehta SR, Xie C, Ahmed RJ, Xavier D, Pais P, Zhu J, Liu L; CREATE Trial Group Investigators. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 2005; 293(4): 427-35.
  2. Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D, Paolasso E, Ahmed R, Xie C, Kazmi K, Tai J, Orlandini A, Pogue J, Liu L; CREATE-ECLA Trial Group Investigators. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 2005; 293(4): 437-46.
  3. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, on behalf of the INTERHEART investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9437): 937-52.
  4. Rosengren A, Hawken S, Ôunpuu S, Sliwa K, Zubaid M, Almahmeed WA, Blackett KN, Sitthi-amorn C, Sato H, Yusuf S for the INTERHEART investigators. Association of psychosocial risk factors with risk of acute myocardial infarction in 11,119 cases and 13,648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9437): 953-62
  5. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2003; 104(22): 2746-53.
  6. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2003; 104(23): 2855-64.
  7. Yusuf S on behalf of the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Trial Investigators. Effects of Clopidogrel in Addition to Aspirin in Patients with Non-ST Segment Elevation Acute Coronary. NEJM 2003;345:494-502.
  8. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. NEJM 2000;342:145-53.
  9. Pogue J, Yusuf S. Overcoming the limitations of current meta-analysis of randomised controlled trials. The Lancet 1998; 351:47-52.
  10. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stats Med 1984;3:409-420.